Health Care & Life Sciences » Pharmaceuticals | IPCA Laboratories Ltd.

IPCA Laboratories Ltd. | Cash Flow

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
6,306
3,611
1,166
2,621
2,905
Depreciation, Depletion & Amortization
1,031
1,796
1,633
1,730
1,777
Other Funds
-
-
-
-
-
Funds from Operations
6,215
4,593
2,755
3,691
3,991
Changes in Working Capital
1,041
187
4,103
1,037
801
Net Operating Cash Flow
5,174
4,406
6,858
2,653
3,191
Capital Expenditures
3,924
5,583
2,471
1,363
1,367
Sale of Fixed Assets & Businesses
11
12
16
19
12
Purchase/Sale of Investments
34
202
297
214
3
Net Investing Cash Flow
3,947
6,957
2,272
1,558
1,358
Cash Dividends Paid - Total
661
369
153
2
153
Issuance/Reduction of Debt, Net
394
3,214
4,144
1,353
926
Net Financing Cash Flow
1,055
2,846
4,298
1,355
1,079
Net Change in Cash
172
294
288
260
753
Free Cash Flow
1,250
1,177
4,387
1,290
1,824
Net Assets from Acquisitions
-
1,184
-
-
-
Other Uses
-
-
114
-
-

About IPCA Laboratories

View Profile
Address
142-AB, Kandivli Industrial Estate
Mumbai Maharashtra 400067
India
Employees -
Website http://www.ipcalabs.com
Updated 09/14/2018
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. It offers active pharmaceuical ingredients such as Atenolol, Chloroquine Phosphate, Furosemide, Hydroxychloroquine Sulphate, Metoprolol Succinate, Metoprolol Tartrate, and Pyrantel Salts. The company was founded on October 19, 1949 and is headquartered in Mumbai, India.